United States Self-Monitoring Blood Glucose Devices
The U.S. Self-Monitoring Blood Glucose Devices market size accounted for USD 4,045 million in 2023 and it is expected to reach around USD 7,138 million by 2032 poised to grow at a noteworthy CAGR of 6.5% during the forecast period from 2024 to 2032.
The global rise in diabetes, fueled by factors such as an aging population, sedentary lifestyles, and unhealthy diets, is a key driver of demand for SMBG devices. Continuous glucose monitoring (CGM) systems are becoming increasingly popular compared to traditional blood glucose meters as they provide real-time insight into glucose levels without the need to take blood samples from the finger.
Smart, connected devices that can be synchronized with mobile apps for better data management and analysis are also on the rise. There is an increasing trend towards patients taking responsibility for their health and trying to manage it from the comfort of their own homes. This has been accelerated by the COVID-19 pandemic, which underlined the importance of remote monitoring and telemedicine.
In many regions, favourable insurance and reimbursement policies for SMBG devices and supplies have supported market growth. However, the extent of coverage varies significantly across different countries and insurance plans.
Given the fast pace of technological innovation and the changing regulatory environment, the market for SMBG devices is likely to continue to evolve rapidly. Manufacturers that focus on improving accuracy, affordability, and ease of use while navigating the complex regulatory environment will thrive in this growing market.
Key Questions Addressed by the Report:
- How many people in the United States have diabetes?
- How many people in the United States use insulin?
- How has the United States self-monitoring blood glucose devices market performed so far?
- How is the United States self-monitoring blood glucose devices market anticipated to evolve during the forecast period 2024 – 2032?
- How is each segment of the United States self-monitoring blood glucose devices market expected to grow during the forecast period, and what is the revenue expected to be generated by each of the segments by the end of 2032?
- What are the main drivers and restraints in the United States self-monitoring blood glucose devices market?
- What are the major deals happening in the United States self-monitoring blood glucose devices market?
- What are the various SMBG devices available in the United States?
- What is the reimbursement scenario of the products offered in the United States self-monitoring blood glucose devices market?
- What is the regulatory system of the self-monitoring blood glucose devices market in the United States?
- Who are the top market players and what are their happenings, products, current developments, and scenarios?
The future of the SMBG market appears promising, with several key trends expected to shape its evolution:
- Integration with Digital Health Platforms: Increased integration with digital health platforms and medical recording systems for comprehensive health management.
- Wearable Technology: The development of non-invasive, wearable technology for continuous glucose monitoring is a potential game-changer, even if there are still significant scientific and regulatory hurdles.
- Personalized Diabetes Management: Advances in data analytics and artificial intelligence (AI) are expected to enable personalized, predictive insights into diabetes management.
The Key Companies Dominating this Market for their Products, Services, and Continuous Product Developments are:
- Roche
- LifeScan, Inc
- Arkray, Inc
- ForaCare, Inc
- Fifty50 Medical
- iHealth Labs
- Oak Tree Health
- Livongo Health
- Dario Health
- One Drop
- Sanofi
- BioTel Care
- Walgreens
- i-SENS, Inc
- Medtronic
- U.S. Diagnostics
- Omnis Health
- Nova Diabetes Care
- Trividia Health, Inc
- Simple Diagnostics
- Smart Meter LLC
- Ascensia Diabetes Care
- Abbott Diabetes Care
- Genesis Health Technologies
- Prodigy Diabetes Care, LLC
- Omron Healthcare
- Ypsomed Holding AG
- Osang Healthcare Co., Ltd
- B. Braun Holding GmbH & Co. KG.
- Entra Health (Acquired by CRF Health)
- Waveform Diabetes (Formerly AgaMatrix Holdings, LLC)
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 190 |
| Forecast Period | 2023 – 2032 |
| Estimated Market Value (USD) in 2023 | $4.05 Billion |
| Forecasted Market Value (USD) by 2032 | $7.14 Billion |
| Compound Annual Growth Rate | 6.5% |
| Regions Covered | United States |
Key Topics Covered:
1. Introduction
2. Research Methodology
3. Executive Summary
4. United States Diabetes Population and Forecast, 2018 – 2032
5. United States Insulin Users Volume and Forecast, 2018 – 2032
6. United States Self-Monitoring Blood Glucose (SMBG) Market Size and Forecast, 2018 – 2032
7. United States Self-Monitoring Blood Glucose (SMBG) Market Share: By Segment
8. United States Self-Monitoring Blood Glucose (SMBG) Market: Segment Analysis and Forecasts, 2018 – 2032
8.1 Blood Glucose Meter Users Volume Assessment
8.2 Blood Glucose Meter Market
8.3 Blood Glucose Test Strip Users Volume Assessment
8.4 Blood Glucose Test Strip Market
8.5 Blood Glucose Lancet Users Volume Assessment
8.6 Blood Glucose Lancet Market
9. Key Market Drivers and Inhibitors of the United States Self-Monitoring Blood Glucose Devices Market
9.1 Market Drivers
9.2 Market Challenges
10. Reimbursement Environment of the United States Self-Monitoring Blood Glucose Devices Market
11. Regulatory Framework of the United States Self-Monitoring Blood Glucose Devices Market
12. Recent Industry Developments and Deals in the Self-Monitoring Blood Glucose Devices Market
12.1 Collaboration Deals
12.2 Licensing Agreement
12.3 Partnership Deals
12.4 Distribution Agreement
12.5 Exclusive Agreement
12.6 Mergers & Acquisitions
13. Key Companies Profiles (Business Overview, Key Marketed Products, and Recent Development)
For more information about this report visit here.
